Propanc Biopharma (PPCB) Short Interest Ratio & Short Volume

Short interest is the volume of Propanc Biopharma shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 300 shares of PPCB short. 1.58% of Propanc Biopharma's shares are currently sold short. Learn More on Propanc Biopharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.58% of Propanc Biopharma's floating shares are currently sold short.

Propanc Biopharma saw a drop in short interest in June. As of June 30th, there was short interest totaling 300 shares, a drop of 25.0% from the previous total of 400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

1.58% of Propanc Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Propanc Biopharma: Biophytis S.A. (0.47%), Virpax Pharmaceuticals, Inc. (0.79%), Viracta Therapeutics, Inc. (0.02%), GLG Life Tech Corp. (0.00%), Nexien Biopharma, Inc. (0.00%), Kiromic BioPharma, Inc. (0.01%), NuCana PLC Sponsored ADR (108.35%), TC Biopharm (Holdings) Plc (176.43%), Syros Pharmaceuticals, Inc. (0.51%), Bon Natural Life Limited (51.46%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

Short selling PPCB is an investing strategy that aims to generate trading profit from Propanc Biopharma as its price is falling. PPCB shares are trading down $0.49 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Propanc Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PPCB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PPCB, twice per month. The most recent reporting period available is June, 30 2025.